The estimated Net Worth of Paul H Klingenstein is at least $33.2 Thousand dollars as of 29 July 2019. Paul Klingenstein owns over 25,862 units of Conatus Pharmaceuticals stock worth over $33,223 and over the last 13 years Paul sold CNAT stock worth over $0.
Paul has made over 3 trades of the Conatus Pharmaceuticals stock since 2011, according to the Form 4 filled with the SEC. Most recently Paul exercised 25,862 units of CNAT stock worth $7,500 on 29 July 2019.
The largest trade Paul's ever made was buying 399,291 units of Conatus Pharmaceuticals stock on 21 November 2011 worth over $5,190,783. On average, Paul trades about 38,041 units every 200 days since 2011. As of 29 July 2019 Paul still owns at least 59,327 units of Conatus Pharmaceuticals stock.
You can see the complete history of Paul Klingenstein stock trades at the bottom of the page.
Paul's mailing address filed with the SEC is C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER, CO, 80301.
Over the last 11 years, insiders at Conatus Pharmaceuticals have traded over $0 worth of Conatus Pharmaceuticals stock and bought 1,570,135 units worth $17,229,485 . The most active insiders traders include Shahzad Malik, Paul H Klingenstein, and Preston Klassen. On average, Conatus Pharmaceuticals executives and independent directors trade stock every 83 days with the average trade being worth of $47,160. The most recent stock trade was executed by Steven J Mento on 4 May 2018, trading 60,000 units of CNAT stock currently worth $59,400.
Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.
Conatus Pharmaceuticals executives and other stock owners filed with the SEC include: